Pharma: Page 62
-
J&J bolsters coronavirus vaccine work with BARDA partnership
Notably, J&J said it would work to "upscale" its production and manufacturing capacity for any vaccine that might result from its research efforts.
By Ned Pagliarulo • Feb. 12, 2020 -
Merck builds case for Keytruda use in breast cancer
When added to chemo, Merck's immunotherapy kept a difficult-to-treat form of breast cancer from progressing, provided patients had an important biomarker.
By Jonathan Gardner • Feb. 12, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Courtesy of Sanofi
Sanofi shrinks executive team as new CEO reshapes French drugmaker
Four members of Sanofi's top leadership will depart, including current chief medical and digital officer Ameet Nathwani.
By Ned Pagliarulo • Feb. 12, 2020 -
Bayer, looking to grow pharmaceutical sales, seeds new research center
The German drugmaker is transferring a "large part" of its small molecule research unit in Berlin to contract developer and manufacturer Nuvisan, with the aim of building a new facility on Bayer's R&D campus.
By Jacob Bell • Feb. 11, 2020 -
In Alzheimer's, a plan to treat patients earlier doesn't work out for Lilly, Roche
Results from the DIAN-TU study chip away at the amyloid hypothesis' foundation, just as Biogen prepares to file its drug aducanumab for approval.
By Jonathan Gardner • Feb. 10, 2020 -
AbbVie's plan to replace Humira is ahead of schedule
Sales of Skyrizi and Rinvoq, AbbVie's two new immunology drugs, jumped higher in the fourth quarter, leading the pharma to raise its 2020 forecasts for them by more than two-thirds.
By Ned Pagliarulo • Feb. 7, 2020 -
Courtesy of Sanofi
Sanofi MS drug results set stage for extensive late-stage testing
The drug, a type of enzyme inhibitor that's proven valuable in cancer treatment, will soon head into four late-stage studies across various types of MS.
By Jacob Bell • Feb. 6, 2020 -
Jacob Bell/BioPharma Dive
Merck joins peers in spinning off lower growth drugs
A yet-to-be-named new company will house Merck's women's health, biosimilar and legacy drugs, providing space and resources for the pharma's higher-growth businesses.
By Jacob Bell • Feb. 5, 2020 -
January price increases confirm slowing drug inflation
Pfizer, GlaxoSmithKline and Allergan were the most active, collectively raising list prices on some 450 drugs, according to one Wall Street analyst.
By Jonathan Gardner • Feb. 4, 2020 -
Bristol-Myers launches biotech targeting fibrosis, inflammation
Anteros Pharmaceuticals is the first company made via a partnership between Bristol-Myers and biotech accelerator BioMotiv. Its initial targets are liver and lung fibrosis, with one specific focus being IPF.
By Jacob Bell • Feb. 4, 2020 -
US cancels trial after finding vaccine doesn't prevent HIV
Research into preventive treatments will continue, however, as an NIH leader declared a vaccine "essential" to ending the widespread disease.
By Jonathan Gardner • Feb. 3, 2020 -
Amgen, Pfizer biosimilar sales pressure top drugs
Competition is heating up for copycats to Roche's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting.
By Jonathan Gardner • Jan. 31, 2020 -
Preventive Alzheimer's trial data due within weeks, Lilly says
Lilly's top scientist, however, set low expectations that solanezumab will show a benefit for patients with genetic mutations that drive early and severe disease.
By Jonathan Gardner • Jan. 30, 2020 -
Adeline Kon/BioPharma Dive
Deep Dive // Brain drug revivalBig pharma backed away from brain drugs. Is a return in sight?
Biotech executives see a new era of neuroscience breakthroughs on the horizon. But in a historically challenging space, it's hard to pinpoint what would cause big pharma to dive back in — and what ripples that would create.
By Jacob Bell • Jan. 29, 2020 -
Zolgensma sales grow, signaling gene therapy momentum
Another 100 infants received Novartis' gene therapy in the fourth quarter, supported by broad insurance coverage and more newborn screening.
By Ned Pagliarulo • Jan. 29, 2020 -
Pfizer lays out gene therapy aspirations
With more Phase 3 trials on the near horizon, the big pharma plans to add one new gene therapy project per year to its pipeline.
By Jonathan Gardner • Jan. 28, 2020 -
To close merger, AbbVie and Allergan sell digestive drug to AstraZeneca
Allergan acquired global rights to brazikumab for $250 million up front in 2016, but expected antitrust conflicts pushed it and AbbVie to pursue a divestment.
By Jonathan Gardner • Jan. 27, 2020 -
Pfizer hits its biosimilar stride
The big pharma, which has criticized other companies for stifling the U.S. biosimilars market, is now poised to launch three of these copycat biologics in as many months.
By Jacob Bell • Jan. 27, 2020 -
Ipsen pauses studies of drug for rare bone disease
The decision makes a mid-2020 approval and launch, which Ipsen expected when it acquired the drug, less likely.
By Jacob Bell • Jan. 24, 2020 -
Permission granted by Roche
Roche strengthens case for SMA drug with new study data
Results showed the oral drug can help improve motor function in babies with the severest form of a rare degenerative muscular disease.
By Jonathan Gardner • Jan. 23, 2020 -
Courtesy of Eli Lilly
Lilly to invest $470M in new North Carolina drug plant
The facility, which will employ more than 400, is part of a broader build-out by Lilly of its manufacturing network.
By Kristin Jensen • Jan. 22, 2020 -
5 biopharmas to watch as the decade's last earnings kick off
Biogen faces down analysts one more time on its aducanumab plans, while two biotechs could give early glimpses into their first-ever drug launches.
By Ned Pagliarulo , Jacob Bell • Jan. 21, 2020 -
Kendall Davis/BioPharma Dive
While expected, Intercept's approval delay adds to NASH uncertainty
An upcoming FDA advisory meeting will be a key test for Intercept's ambitions to become the first drugmaker with an approved therapy for the liver disease.
By Jacob Bell • Jan. 17, 2020 -
Lilly seeking out more 'Dermira-like' deals: report
The pharma is targeting deals between $1 billion and $5 billion every quarter, its CFO told Reuters, although the focus will be on clinical-stage assets.
By Jonathan Gardner • Jan. 17, 2020 -
Danielle Ternes/BioPharma Dive
Neuroscience's decade, a biotech's 'crown jewel,' and Ionis gets selective
Roche, maker of the last decade's top cancer drugs, is betting that neuroscience R&D can make strides in the 2020s — an outlook that contrasts with research retreats by the pharma's peers.
By Andrew Dunn , Jacob Bell • Jan. 15, 2020
Previous
